Safety and preliminary activity data from a single center phase II study of triplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [trident] in patients (Pts) with BRAF-mutated metastatic melanoma (MM).
暂无分享,去创建一个
J. McQuade | J. Wargo | R. Amaria | H. Tawbi | S. Patel | P. Hwu | S. Woodman | E. Burton | C. Yee | W. Hwu | I. Glitza | D. Milton | M. Shephard | M. Wong | M. Davies | Michael Shephard | Karen Mae Perdon